Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study

Clin Neuropharmacol. Jul-Aug 2003;26(4):193-5. doi: 10.1097/00002826-200307000-00008.

Abstract

A double-blind, placebo-controlled crossover study was undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction. Selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels (P < 0.05). This study emphasizes the complex nature of sexual dysfunction in schizophrenic-treated patients and the need for placebo-controlled trials for this condition.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Cross-Over Studies
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Prolactin / blood
  • Schizophrenia / blood
  • Schizophrenia / drug therapy*
  • Selegiline / therapeutic use*
  • Sexual Dysfunctions, Psychological / blood
  • Sexual Dysfunctions, Psychological / drug therapy*

Substances

  • Antipsychotic Agents
  • Selegiline
  • Prolactin